ADAM AND AMS SCALE FOR ASSESSING ANDROPAUSE AMONG AGING INDIAN MEN
Keywords:
Andropause, Awareness, Knowledge, India, ADAM scale, AMS scaleAbstract
Objective: According to Indian Census 2011, India has 9% of population above the age of 60 years. Since andropause related effects are gradual and mimic many disease processes, clinical diagnosis is difficult to make. Very few studies have been done in North India to assess the awareness about andropause in males, which is why this study was conceived. To assess the awareness and knowledge about Andropause and its treatment modalities in males of Chandigarh.
Methods: The present study was conducted at Urban Health Training Centre (UHTC-44 B) of Government Medical College and Hospital, Sector 32, Chandigarh (GMCH) in male patients attending outpatient department. This non-interventional, individual cross sectional study was done from Aug 2010- Aug 2011 in males 40 years and above. Systematic random sampling was done and study sample comprised of 757 males. The subjects were given pre-structured and pre-tested questionnaire that had questions pertaining to socio-demographic profile, Ageing Men Score scale (AMS scale), ADAM scale (Androgen Decline in Ageing Men), views about andropause and its treatment modalities.
Results: Maximum subjects were from age group 40-49yrs (342; 45.17%), followed by those in age group of 60-69 years (141; 18.6%). 530 respondents (70%) indicated previous awareness regarding andropause or male menopause. Among andropause aware subjects, 440 (83.02%) respondents had poor knowledge about andropause and only 90 (16.98%) test takers actually had good knowledge about andropause. Age and marital status had little effect on knowledge of andropause. 627 (82.82%) had symptoms positive for andropause. Only 123 (19.61%) respondents were aware of treatment for andropause, 158 (25.21%) were willing to take treatment for andropause in form of testosterone injections or transdermal patches when informed about treatment options by health care workers. 360 (57.41%) respondents believed that healthy diet, exercise, herbal medications, Viagra and/or multivitamins can be used to treat andropause and refused to take testosterone injections. Remaining 239 (38.11%) respondents were not able to decide whether they want to take any treatment for andropause.
Conclusion: Though awareness about andropause was seen among most men but the study shows the need for provision of health education to increase the knowledge of andropause among adult males.
Downloads
References
Government of India: Population Totals†Census; 2011. Available: http://www.censusindia.gov.in/2011-prov-results/data_files/mp/Final Data Sheet_mp. pdf. [Accessed: 10 Sep. 2013].
Handelsman DJ, Liu PY. Andropause: invention, prevention, rejuvenation. Trends Endocrinol Metab 2005;16(2):39-45.
Demers LM. Andropause: an androgen deficiency state in the ageing male. Expert Opin Pharmacother 2003;4(2):183-90.
Delev DP, Kostadinova II, Kostadinov ID, Ubenova DK. Physiological and clinical characteristics of andropause. Folia Med (Plovdiv) 2009;51(1):15-22.
Kocoglu H, Alan C, Soydan H, Ates F, Adayener C, Eren AE, et al. Association between the androgen levels and erectile function, cognitive functions and hypogonadism symptoms in aging males. Aging Male 2011;14(4):207-12.
Morales A, Spevack M, Emerson L, Kuzmarov I, Casey R, Black A, et al. Adding to the controversy: pitfalls in the diagnosis of testosterone deficiency syndromes with questionnaires and biochemistry. Aging Male 2007;10(2):57-65.
Rabah DM, Arafa MA. Validation of an Arabic ADAM questionnaire for androgen deficiency screening in the Arab community. Aging Male 2009;12(4):95-9.
Heinemann LA. Aging Males' Symptoms scale: a standardized instrument for the practice. J Endocrinol Invest 2005;28(11):34-8.
Blumel JE, Chedraui P, Gili SA, Navarro A, Valenzuela K, Vallejo S. Is the Androgen deficiency of aging men (ADAM) questionnaire useful for the screening of partial androgenic deficiency of aging men?. Maturitas 2009;63(4):365-8.
Winn RL, Newton N. Sexuality in aging: a study of 106 cultures. Arch Sex Behav 1982;11(4):283-98.
George LK, Weiler SJ. Sexuality in middle and late life. The effects of age, cohort, and gender. Arch Gen Psychiatry 1981;38(8):919-23.
Tan RS, Philip PS. Perceptions of and risk factors for andropause. Arch Androl 1999;43(3):227-33.
Yan YY. Awareness and knowledge of andropause among Chinese males in Hong Kong. Am J Mens Health 2010;4(3):231-6.
Adebajo S, Odeyemi K, Oyediran M, Anorlu R, Wright L. Knowledge and experiences of andropause among men in Lagos, Nigeria. West Afr J Med 2007;26(2):106-12.
Fatusi AO, Ijadunola KT, Ojofeitimi EO, Odumabo AO, Adewuyi AA, Akinyemi A, et al. The influence of sociodemographic factors on awareness, knowledge and attitude toward andropause among health professionals in Ile-Ife, Nigeria. Aging Male 2004;7(4):269-79.
Jockenhovel F. Testosterone therapy--what, when and to whom? Aging Male 2004;7(4):319-24.
Kaphle K, Wu LS, Yang NY, Lin JH. Herbal medicine research in Taiwan. Evid Based Complement Alternat Med 2006;3(1):149-55.
Steidle CP. New advances in the treatment of hypogonadism in the aging male. Rev Urol 2003;5 Suppl 1:S34-40.